tradingkey.logo

OmniAb Inc

OABI
View Detailed Chart
1.380USD
-0.045-3.16%
Close 11/06, 16:00ETQuotes delayed by 15 min
198.66MMarket Cap
LossP/E TTM

OmniAb Inc

1.380
-0.045-3.16%
Intraday
1m
30m
1h
D
W
M
D

Today

-3.16%

5 Days

-7.38%

1 Month

-17.86%

6 Months

-10.97%

Year to Date

-61.02%

1 Year

-70.32%

View Detailed Chart

TradingKey Stock Score of OmniAb Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

OmniAb Inc's Score

Industry at a Glance

Industry Ranking
138 / 407
Overall Ranking
263 / 4615
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
7.333
Target Price
+414.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

OmniAb Inc Highlights

StrengthsRisks
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Growing
The company is in a growing phase, with the latest annual income totaling USD 26.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 26.39M.
Overvalued
The company’s latest PE is -2.34, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.66M shares, decreasing 20.50% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 84.05K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.18.

OmniAb Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

OmniAb Inc Info

OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Ticker SymbolOABI
CompanyOmniAb Inc
CEOMr. Matthew William (Matt) Foehr
Websitehttps://www.omniab.com/
KeyAI